Vitro Diagnostics Inc (fka VODG)

[Potse]

Vitropin commercialization statement....

The first quarter report also reiterates VODG's expectation that the company's fertility drug (Vitropin) will experience commercialization during 2013. That would roughly fit into the 2.5-year (March 2011 - September 2013) revenue-production time frame that VODG and James Posillico had settled on in the license agreement.

I had assumed/guessed that commercialization would probably require more time, but since CEO Musick doesn't seem to be backing away or hedging on the statement, it would seem that Posillico must be fairly confident that he can begin commercialization this year.

It should be very interesting to see what the reaction from the pump/promotion types of websites and/or momentum groups/players will be. Depending on what VODG will be permitted to say/PR about the commercialization, the "optics" of a low-priced biotech getting a drug commercialized by someone like James Posillico will probably raise a few eyebrows.

Posillico knows the fertility-related market about as well as anybody out there (and has extensive experience/contacts in the venture capital and financing areas), so outside of VODG licensing its drug technology to one of the existing biotechs/biopharmas in the space VODG probably couldn't ask for a better licensee than Posillico.

The 10Q (2013 3Q) that VODG filed on Monday is now the fourth consecutive periodic report that contains a statement referencing an expectation that Vitropin will see commercialization during 2013.